ERBB2 and breast carcinoma: TNBCs are more aggressive, are less likely to be detected by mammography screening than other breast cancers (3), and do not respond to therapies targeting the estrogen or HER2 pathways, making TNBCs more deadly than hormone receptor positive subtypes (4).